NCT02718833View on ClinicalTrials.gov

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 21, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

Elotuzumab

DRUG

Pomalidomide

DRUG

Bortezomib

DRUG

Dexamethasone

Trial Locations (6)

14642

University of Rochester, Rochester

48109

University of Michigan, Ann Arbor

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Dana-Farber Cancer Institute, Boston

01923

Mass General/North Shore Cancer Center, Danvers

02462

Newton-Wellesley Hospital, Newton

Sponsors
All Listed Sponsors
collaborator

Celgene

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Multiple Myeloma Research Consortium

NETWORK

lead

Massachusetts General Hospital

OTHER

NCT02718833 - A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | Biotech Hunter | Biotech Hunter